Edward Tenthoff
Stock Analyst at Piper Sandler
(2.15)
# 2,661
Out of 4,829 analysts
179
Total ratings
36.26%
Success rate
-4.92%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Edward Tenthoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARVN Arvinas | Reiterates: Overweight | $24 → $14 | $6.61 | +111.80% | 7 | May 2, 2025 | |
| IPSC Century Therapeutics | Maintains: Overweight | $4 → $2 | $0.54 | +272.44% | 8 | Mar 20, 2025 | |
| DYN Dyne Therapeutics | Maintains: Overweight | $53 → $48 | $11.41 | +320.68% | 6 | Feb 28, 2025 | |
| MESO Mesoblast | Reiterates: Overweight | $15 → $24 | $10.97 | +118.78% | 5 | Feb 7, 2025 | |
| LEGN Legend Biotech | Reiterates: Overweight | $78 | $31.78 | +145.44% | 4 | Dec 30, 2024 | |
| XNCR Xencor | Upgrades: Overweight | $20 → $30 | $8.33 | +260.14% | 4 | Dec 2, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Overweight | $62 → $45 | $13.03 | +245.36% | 11 | Nov 27, 2024 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Overweight | $296 | $251.15 | +17.86% | 13 | Nov 18, 2024 | |
| MRNA Moderna | Reiterates: Overweight | $115 → $69 | $24.25 | +184.54% | 12 | Nov 18, 2024 | |
| KRON Kronos Bio | Downgrades: Neutral | $6 → $1 | $0.72 | +38.58% | 7 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $65 | $6.49 | +901.54% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $2.13 | +745.07% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $6.34 | +452.05% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 | $0.87 | +1,162.19% | 6 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $1.81 | +1,004.97% | 3 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.24 | +141.94% | 6 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $3 | $0.78 | +284.76% | 4 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $4.09 | +291.20% | 3 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $105 | $35.62 | +194.78% | 6 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $4 → $6 | $1.04 | +476.92% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.11 | +350.45% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $15 | $5.36 | +179.85% | 3 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $56 | $30.07 | +86.23% | 4 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $31 | $0.75 | +4,014.13% | 5 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $3.37 | +2,570.62% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $6 | $0.45 | +1,245.29% | 4 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $180 | $7.06 | +2,451.38% | 3 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $44 | $16.66 | +164.18% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $37 | $8.34 | +343.65% | 2 | May 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $112,332 → $32,560 | $0.34 | +9,576,370.59% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $250 → $354 | $549.27 | -35.55% | 4 | Nov 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $135 | $1.12 | +11,953.57% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $323 | $424.99 | -24.00% | 6 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $36 | $36.17 | -0.47% | 2 | Feb 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $25 | $1.17 | +2,036.75% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $150 | $0.71 | +21,176.60% | 1 | Jan 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $53 | $1.13 | +4,590.27% | 2 | Jan 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,380 | $0.74 | +186,386.49% | 1 | Dec 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $527.78 | - | 11 | Feb 13, 2017 |
Arvinas
May 2, 2025
Reiterates: Overweight
Price Target: $24 → $14
Current: $6.61
Upside: +111.80%
Century Therapeutics
Mar 20, 2025
Maintains: Overweight
Price Target: $4 → $2
Current: $0.54
Upside: +272.44%
Dyne Therapeutics
Feb 28, 2025
Maintains: Overweight
Price Target: $53 → $48
Current: $11.41
Upside: +320.68%
Mesoblast
Feb 7, 2025
Reiterates: Overweight
Price Target: $15 → $24
Current: $10.97
Upside: +118.78%
Legend Biotech
Dec 30, 2024
Reiterates: Overweight
Price Target: $78
Current: $31.78
Upside: +145.44%
Xencor
Dec 2, 2024
Upgrades: Overweight
Price Target: $20 → $30
Current: $8.33
Upside: +260.14%
Arrowhead Pharmaceuticals
Nov 27, 2024
Maintains: Overweight
Price Target: $62 → $45
Current: $13.03
Upside: +245.36%
Alnylam Pharmaceuticals
Nov 18, 2024
Reiterates: Overweight
Price Target: $296
Current: $251.15
Upside: +17.86%
Moderna
Nov 18, 2024
Reiterates: Overweight
Price Target: $115 → $69
Current: $24.25
Upside: +184.54%
Kronos Bio
Nov 14, 2024
Downgrades: Neutral
Price Target: $6 → $1
Current: $0.72
Upside: +38.58%
Nov 13, 2024
Maintains: Overweight
Price Target: $104 → $65
Current: $6.49
Upside: +901.54%
Nov 5, 2024
Initiates: Overweight
Price Target: $18
Current: $2.13
Upside: +745.07%
Oct 21, 2024
Initiates: Overweight
Price Target: $35
Current: $6.34
Upside: +452.05%
Oct 11, 2024
Reiterates: Overweight
Price Target: $11
Current: $0.87
Upside: +1,162.19%
Sep 20, 2024
Reiterates: Overweight
Price Target: $20
Current: $1.81
Upside: +1,004.97%
Sep 17, 2024
Reiterates: Overweight
Price Target: $3
Current: $1.24
Upside: +141.94%
Jul 26, 2024
Maintains: Overweight
Price Target: $8 → $3
Current: $0.78
Upside: +284.76%
Jun 28, 2024
Reiterates: Overweight
Price Target: $16
Current: $4.09
Upside: +291.20%
Jun 17, 2024
Reiterates: Overweight
Price Target: $105
Current: $35.62
Upside: +194.78%
Jun 17, 2024
Upgrades: Overweight
Price Target: $4 → $6
Current: $1.04
Upside: +476.92%
Mar 5, 2024
Maintains: Overweight
Price Target: $6 → $5
Current: $1.11
Upside: +350.45%
Feb 28, 2024
Maintains: Overweight
Price Target: $13 → $15
Current: $5.36
Upside: +179.85%
Feb 27, 2024
Maintains: Overweight
Price Target: $39 → $56
Current: $30.07
Upside: +86.23%
Aug 14, 2023
Maintains: Overweight
Price Target: $28 → $31
Current: $0.75
Upside: +4,014.13%
Dec 12, 2022
Initiates: Overweight
Price Target: $90
Current: $3.37
Upside: +2,570.62%
Nov 4, 2022
Maintains: Overweight
Price Target: $13 → $6
Current: $0.45
Upside: +1,245.29%
Sep 7, 2022
Maintains: Overweight
Price Target: $140 → $180
Current: $7.06
Upside: +2,451.38%
Aug 25, 2022
Maintains: Overweight
Price Target: $37 → $44
Current: $16.66
Upside: +164.18%
May 23, 2022
Maintains: Overweight
Price Target: $76 → $37
Current: $8.34
Upside: +343.65%
May 13, 2022
Maintains: Overweight
Price Target: $112,332 → $32,560
Current: $0.34
Upside: +9,576,370.59%
Nov 29, 2021
Upgrades: Overweight
Price Target: $250 → $354
Current: $549.27
Upside: -35.55%
Sep 20, 2021
Maintains: Overweight
Price Target: $105 → $135
Current: $1.12
Upside: +11,953.57%
Jul 30, 2021
Maintains: Overweight
Price Target: $261 → $323
Current: $424.99
Upside: -24.00%
Feb 16, 2021
Maintains: Overweight
Price Target: $33 → $36
Current: $36.17
Upside: -0.47%
May 12, 2020
Downgrades: Neutral
Price Target: $50 → $25
Current: $1.17
Upside: +2,036.75%
Jan 27, 2020
Initiates: Overweight
Price Target: $150
Current: $0.71
Upside: +21,176.60%
Jan 6, 2020
Maintains: Overweight
Price Target: $26 → $53
Current: $1.13
Upside: +4,590.27%
Dec 11, 2017
Initiates: Overweight
Price Target: $1,380
Current: $0.74
Upside: +186,386.49%
Feb 13, 2017
Upgrades: Overweight
Price Target: n/a
Current: $527.78
Upside: -